In today’s rapidly evolving scientific landscape, eliminating barriers to progress is more critical than ever. Precision medicine and targeted therapies hold great promise but are dependent on the ...
– Initial translational results support proof-of-mechanism with immune reprogramming resulting in tumor penetration and pro-inflammatory alteration in the TME – CAMBRIDGE, Mass., May 30, 2025 ...
Cancer cells have softer membranes than healthy cells. New nanoparticles exploit this physical difference to fuse selectively ...
Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...
Intismeran autogene with pembrolizumab shows a 49% reduction in recurrence or death risk in patients with high-risk resected melanoma over 5 years. The personalized mRNA therapy targets ...
Scientists developed a groundbreaking class of mRNA medicines that can sense changes in the body and autonomously adjust their therapeutic effect. The new mRNA medicine works by responding to specific ...
-- Financing oversubscribed; proceeds from the round will be used to expand Strand’s growing mRNA platforms into multiple immuno-oncology and disease settings, and advance lead drug into Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results